
Abstract

The present invention relates to a compound represented by the following formula (I):




(I)



*162162*

(wherein, W represents $W^A$-$A^1$-$W^B$- (in which, $W^A$ is substituted or unsubstituted aryl, etc., $A^1$ is $-NR^1-$, single bond, -C(O)-, etc., and $W^B$ is substituted or unsubstituted arylene, etc.), R is single bond, -NH-, $-OCH_2-$, alkenylene, etc., X is -C(O)-, $-CH_2-$, etc., and M is, for example, the following formula:





*G00002*

(iii)

(in which, $R^{11}$, $R^{12}$ and $R^{13}$ each independently represents hydrogen, hydroxyl, amino, halogen, etc., $R^{14}$ is hydrogen or lower alkyl, Y represents $-CH_2-O-$, etc., Z is substituted or unsubstituted arylene, etc., $A^2$ is single bond, etc, and $R^{10}$ is hydroxyl or lower alkoxy)), or salt thereof; and a medicament containing the same.

This compound or salt thereof selectively inhibits binding of cell adhesion molecules to VAL-4 and exhibits high bioavailability so that it is useful as a preventive

and/or remedy for inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, diabetes, and the like.